Peng Z#, Wei J#, Wang F, Ying J, Deng Y, Gu K, Cheng Y, Yuan X, Xiao J, Tai Y, Wang L, Zou J, Zhang Y*, Shen L*. Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.,Clinical Cancer Research,27(11):3069-3078.

Peng Z#, Cheng S#, Kou Y, Wang Z, Jin R, Hu H, Zhang X, Gong JF, Li J, Lu M, Wang X, Zhou J, Lu Z, Zhang Q, Tzeng DTW, Bi D, Tan Y, Shen L*. The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer.,Cancer Immunology Research,8(10):1251-1261.

Xie T, Zhang Z, Qi C, Lu M, Zhang X, Li J, Shen L, Peng Z. The Inconsistent and Inadequate Reporting Of Immune-Related Adverse Events in PD-1/PD-L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials.,Oncologist,doi: 10.1002/onco.13940.

Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study,Cancer Commun (Lond),41(11):1173-1182

Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.,J Immunother Cancer,2022 Mar;10(3)

肠道菌群调控胃肠肿瘤免疫治疗疗效的免疫机制研究, 课题负责人, 2021.10.12～2024.10.15, 北京市自然科学基金重点研究专题项目

EBV相关胃癌免疫微环境特征及其在评估免疫治疗疗效中的作用, 课题负责人, 2021.1.1～2022.12.31, 北京大学